NewsBenzingaBarclays avvia la copertura su TransMedics Group con rating Overweight, annuncia un obiettivo di prezzo di 120 dollari Barclays avvia la copertura su TransMedics Group con rating Overweight, annuncia un obiettivo di prezzo di 120 dollari Benzinga 2026.10.07 13:19 (GMT+0) Open on Benzinga Other news 'Former Tesla Optimus Lead is Launching an Industrial Robot Startup'- The Information Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114 Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359 HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22 Morgan Stanley Maintains Equal-Weight on Alcoa, Lowers Price Target to $50 Google Prepares Antigravity For Gemini 4 Argon And Concierge
